Evidence map›Paper›PMID 37169744›Full record

ArticleNature communications2023

Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant.

Jumpei Ito, Rigel Suzuki, Keiya Uriu, Yukari Itakura, Jiri Zahradnik, Kanako Terakado Kimura, Sayaka Deguchi, Lei Wang, Spyros Lytras, Tomokazu Tamura and 30 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed
29.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

92 citing papers in PubMed, 150 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

40 authors at 17 institutions in 6 countries.

Jumpei Ito *Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0003-0440-8321
Rigel Suzuki *Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Keiya Uriu *Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Yukari Itakura *Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.ORCID 0000-0002-3463-1834
Jiri Zahradnik *Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0002-8698-4236
Kanako Terakado Kimura *Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.
Sayaka Deguchi *Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.
Lei Wang *Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.ORCID 0000-0001-6145-395X
Spyros Lytras *Medical Research Council-University of Glasgow Centre for Virus Research, Glasgow, UK.ORCID 0000-0003-4202-6682
Tomokazu TamuraDepartment of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Izumi KidaDivision of Risk Analysis and Management, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.ORCID 0000-0002-6312-1454
Hesham NasserDivision of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan.ORCID 0000-0001-9163-1665
Maya ShofaDepartment of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan.
Mst Monira BegumDivision of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan.
Masumi TsudaDepartment of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.ORCID 0000-0001-5400-5905
Yoshitaka OdaDepartment of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Tateki SuzukiLaboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.ORCID 0000-0002-6946-3850
Jiei SasakiLaboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.
Kaori Sasaki-TabataDepartment of Medicinal Sciences, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
Shigeru FujitaDivision of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0001-9008-2123
Kumiko YoshimatsuInstitute for Genetic Medicine, Hokkaido University, Sapporo, Japan.ORCID 0000-0002-0062-2753
Hayato ItoDepartment of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Naganori NaoDivision of International Research Promotion, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
Hiroyuki AsakuraTokyo Metropolitan Institute of Public Health, Tokyo, Japan.
Mami NagashimaTokyo Metropolitan Institute of Public Health, Tokyo, Japan.
Kenji SadamasuTokyo Metropolitan Institute of Public Health, Tokyo, Japan.
Kazuhisa YoshimuraTokyo Metropolitan Institute of Public Health, Tokyo, Japan.
Yuki YamamotoHiLung, Inc, Kyoto, Japan.
Tetsuharu NagamotoHiLung, Inc, Kyoto, Japan.
Jin KuramochiInterpark Kuramochi Clinic, Utsunomiya, Japan.ORCID 0000-0002-9078-0527
Gideon SchreiberDepartment of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0002-2922-5882
Genotype to Phenotype Japan (G2P-Japan) Consortium
Akatsuki SaitoDepartment of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan.ORCID 0000-0002-2792-4399
Keita MatsunoDivision of Risk Analysis and Management, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.ORCID 0000-0002-4205-6526
Kazuo TakayamaCenter for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.
Takao HashiguchiLaboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan. hashiguchi.takao.1a@kyoto-u.ac.jp.ORCID 0000-0001-7578-7571
Shinya TanakaDepartment of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan. tanaka@med.hokudai.ac.jp.ORCID 0000-0001-6470-3301
Takasuke FukuharaDepartment of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan. fukut@pop.med.hokudai.ac.jp.ORCID 0000-0001-5471-8331
Terumasa IkedaDivision of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan. ikedat@kumamoto-u.ac.jp.ORCID 0000-0003-2869-9450
Kei SatoDivision of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. KeiSato@g.ecc.u-tokyo.ac.jp.ORCID 0000-0003-4431-1380
Kyoto University · JPHokkaido University · JPThe University of Tokyo · JPKumamoto University · JPTokyo Metropolitan Institute of Public Health · JPUniversity of Miyazaki · JPSapporo University · JPHiroshima University · JPTokai University · JPCharles University · CZKyushu University · JPMRC University of Glasgow Centre for Virus Research · GBNational Institute of Infectious Diseases · JPSuez Canal University · EGTokyo Medical and Dental University · JPUniversity Children's Hospital Tübingen · DEWeizmann Institute of Science · IL

Funding

Medical Research Council MC_PC_19026
6 · The paper itself

Abstract

In late 2022, various Omicron subvariants emerged and cocirculated worldwide. These variants convergently acquired amino acid substitutions at critical residues in the spike protein, including residues R346, K444, L452, N460, and F486. Here, we characterize the convergent evolution of Omicron subvariants and the properties of one recent lineage of concern, BQ.1.1. Our phylogenetic analysis suggests that these five substitutions are recurrently acquired, particularly in younger Omicron lineages. Epidemic dynamics modelling suggests that the five substitutions increase viral fitness, and a large proportion of the fitness variation within Omicron lineages can be explained by these substitutions. Compared to BA.5, BQ.1.1 evades breakthrough BA.2 and BA.5 infection sera more efficiently, as demonstrated by neutralization assays. The pathogenicity of BQ.1.1 in hamsters is lower than that of BA.5. Our multiscale investigations illuminate the evolutionary rules governing the convergent evolution for known Omicron lineages as of 2022.

Indexed as

COVID-19Amino Acid SubstitutionAnimalsAntibodies, NeutralizingAntibodies, ViralBiological AssayCricetinaePhylogenySARS-CoV-2Antibodies, NeutralizingAntibodies, Viral

Identifiers

PMID37169744
PMCPMC10175283
OpenAlexW4376223660

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.